Enhancement of Radiosensitivity of the MCF-7 Breast Cancer Cell Line with Human Chorionic Gonadotropin

被引:0
作者
Sunthorn Pond-Tor
Ryan G. Rhodes
Paul E. Dahlberg
John T. Leith
John McMichael
Albert E. Dahlberg
机构
[1] Milkhaus Laboratory,Department of Molecular and Cell Biology & Biochemistry
[2] Inc.,undefined
[3] Department of Radiation Oncology,undefined
[4] Brown University Medical School,undefined
来源
Breast Cancer Research and Treatment | 2002年 / 72卷
关键词
breast cancer; chorionic gonadotropin; MCF-7; MTT; radiosensitivity;
D O I
暂无
中图分类号
学科分类号
摘要
Secretion of human chorionic gonadotropin (hCG) during pregnancy induces differentiation of the mammary gland, thereby making breast tissue less susceptible to carcinogenesis. HCG binds to specific hCG receptors on mammary epithelial cells inducing changes in gene expression that can inhibit cell proliferation and, therefore, interfere with tumorigenesis. Since breast cancer cells also contain a relatively high level of the hCG receptor, hCG has potential as a therapeutic agent. We postulated that hCG might also enhance the radiosensitivity of breast cancer cells and, therefore, be useful as an adjunctive therapy. In the present study, MCF-7 breast cancer cells grown in cell culture were treated with hCG (0.2–5 IU/ml) for 24 h prior to exposing the cells to 0 Gy, 3 Gy, 4 Gy, or 5 Gy of radiation. Following irradiation, the MCF-7 cells were incubated either in the presence or absence of hCG. Cell survival was monitored with an MTT assay 1 day, 4 days, and 7 days after irradiation. All of the concentrations of hCG tested enhanced radiosensitivity of MCF-7 cells. The maximum enhancement occurred with MCF-7 cells that had been exposed to 2 IU/ml of hCG for at least 24 h prior to irradiation with 4 Gy. The use of higher concentrations of hCG or a higher dose of radiation did not increase the enhancement effect. Treatment of MCF-7 cells with hCG for only 24 h was sufficient to achieve the maximum effect. However, maintaining the cells in hCG beyond 24 h increased the effectiveness of the lowest hCG concentration. Using a linear-quadratic equation to analyze the data, we determined that the use of hCG would result in an 8–10% reduction in MCF-7 cell survival at a dose of 2 Gy, a typical dose used in conventional cancer therapy.
引用
收藏
页码:45 / 51
页数:6
相关论文
共 135 条
[1]  
Klavins JV(1983)Advances in biological markers for cancer Ann Clin Lab Sci 13 275-280
[2]  
Acevedo HF(1992)Expression of membraneassociated human chorionic gonadotropin, its subunits, and fragments by cultured human cancer cells Cancer 69 1829-1842
[3]  
Krichevsky A(1996)Metastatic phenotype correlates with high expression of membrane-associated complete betahuman chorionic gonadotropin Cancer 78 2388-2399
[4]  
Campbell-Acevedo EA(1989)Lutropinchoriogonadotropin receptor: an unusual member of the G protein-coupled receptor family Science 245 494-499
[5]  
Galyon JC(1996)The beginning of a new era in reproductive biology and medicine: expression of low levels of functional luteinizing hormone/human chorionic gonadotropin receptors in nongonadal tissues J Physiol Pharmacol 47 41-53
[6]  
Buffo MJ(1995)Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone Nature 375 64-68
[7]  
Hartsock RJ(1996)The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma N Engl J Med 335 1261-1269
[8]  
Acevedo HF(1997)Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous Kaposi's sarcoma J Natl Cancer Inst 89 1797-1802
[9]  
Hartsock RJ(1998)Modulating activity of human chorionic gonadotropin on growth and tumorigenesis of prostate cancer cells Mol Urol 2 57-63
[10]  
McFarland KC(1997)Expression of luteinizing hormone/human chorionic gonadotropin receptor gene in benign prostatic hyperplasia and in prostate carcinoma in humans Biol Reprod 56 67-72